T1	Participants 104 143	advanced upper gastrointestinal cancer.
T2	Participants 220 278	patients with upper gastrointestinal adenocarcinoma (UGIA)
T3	Participants 291 348	Seventy-three patients with advanced UGIA were randomised
T4	Participants 847 889	Patients with normal levels, except CA72-4
T5	Participants 1349 1395	patients with UGIA on palliative chemotherapy.
